Table 1.
Trial | No. patients | Chemotherapy | Radiation dose | 5-Year survival (%) |
---|---|---|---|---|
Araujo et al.85 | ||||
RT | 28 | 5-FU, MMC, Bleomycin | 50 | 6 |
chemoradiotherapy | 31 | 50 | 16 | |
Slabber et al.86 | ||||
RT | 34 | 40 SC | 6 months† | |
chemoradiotherapy | 36 | 5-FU | 40 SC | 5 months |
*Smith et al.87 | ||||
RT | 62 | 40–60 | 7 | |
chemoradiotherapy | 65 | 5-FU, MMC | 40–60 | 9 |
Wobbes, et al.88 | ||||
RT | 111 | 40 SC | 7.9 months† | |
chemoradiotherapy | 110 | Cisplatin | 40 SC | 9.6 months |
Herskovic et al.3 | ||||
RT | 62 | 64 | 0 | |
chemoradiotherapy | 61 | Cisplatin, 5-FU | 50 | 26 |
Zupanc. et al.89 | ||||
RT | 52 | 60 non-SC | 14.5 | |
chemoradiotherapy | 55 | Cisplatin, 5-FU | 40 SC | 24.5 |
Surgery allowed after 40 Gy
Median Survival
Abbreviations: RT = radiotherapy; 5-FU = 5-fluorouracil; MMC = mitomycin C; SC = split course